{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T16:30:07Z","timestamp":1793464207996,"version":"4.5.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s40261-026-01593-5","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T13:54:40Z","timestamp":1788875680000},"page":"1209-1212","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Great Transatlantic Divide: The Case of Experimental Neuropharmacology"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2216-3973","authenticated-orcid":false,"given":"Carlo","family":"Colosimo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"1593_CR1","doi-asserted-by":"publisher","first-page":"797","DOI":"10.2147\/CIA.S325026","volume":"17","author":"M Vaz","year":"2022","unstructured":"Vaz M, Silva V, Monteiro C, Silvestre S. Role of aducanumab in the treatment of Alzheimer\u2019s disease: challenges and opportunities. Clin Interv Aging. 2022;17:797\u2013810. https:\/\/doi.org\/10.2147\/CIA.S325026.","journal-title":"Clin Interv Aging"},{"key":"1593_CR2","doi-asserted-by":"publisher","first-page":"969","DOI":"10.3233\/JAD-215105","volume":"84","author":"M Kurkinen","year":"2021","unstructured":"Kurkinen M, Tran L. Aduhelm: the best hope for Alzheimer\u2019s disease patients or the worst decision the FDA has ever made? J Alzheimers Dis. 2021;84:969\u201371. https:\/\/doi.org\/10.3233\/JAD-215105.","journal-title":"J Alzheimers Dis"},{"key":"1593_CR3","doi-asserted-by":"publisher","first-page":"32","DOI":"10.9740\/mhc.2022.01.032","volume":"12","author":"L Cummins","year":"2022","unstructured":"Cummins L, Cates ME. Istradefylline: a novel agent in the treatment of \u201coff\u201d episodes associated with levodopa\/carbidopa use in Parkinson disease. Ment Health Clin. 2022;12:32\u20136. https:\/\/doi.org\/10.9740\/mhc.2022.01.032.","journal-title":"Ment Health Clin"},{"key":"1593_CR4","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1177\/10600280231172802","volume":"58","author":"A Alqallaf","year":"2024","unstructured":"Alqallaf A, Cates DW, Render KP, Patel KA. Sodium phenylbutyrate and taurursodiol: a new therapeutic option for the treatment of amyotrophic lateral sclerosis. Ann Pharmacother. 2024;58:165\u201373. https:\/\/doi.org\/10.1177\/10600280231172802.","journal-title":"Ann Pharmacother"},{"key":"1593_CR5","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1080\/14737175.2024.2333970","volume":"24","author":"ER Schiller","year":"2024","unstructured":"Schiller ER, Silverglate BD, Grossberg GT. Profiling lecanemab as a treatment option for Alzheimer\u2019s disease. Expert Rev Neurother. 2024;24:433\u201341. https:\/\/doi.org\/10.1080\/14737175.2024.2333970.","journal-title":"Expert Rev Neurother"},{"key":"1593_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.r778","volume":"389","author":"S Bakchine","year":"2025","unstructured":"Bakchine S, Colosimo C, Emilsson E, J\u00f3nsd\u00f3ttir SE, Massacesi L, Nonino F, et al. Concerns about the approval of lecanemab for Alzheimer\u2019s disease. BMJ. 2025;389:r778. https:\/\/doi.org\/10.1136\/bmj.r778.","journal-title":"BMJ"},{"key":"1593_CR7","doi-asserted-by":"publisher","first-page":"4583","DOI":"10.1007\/s00415-023-11864-2","volume":"270","author":"E Mercuri","year":"2023","unstructured":"Mercuri E, Osorio AN, Muntoni F, Buccella F, Desguerre I, Kirschner J, et al. Correction to: safety and effectiveness of ataluren in patients with nonsense mutation DMD in the STRIDE registry compared with the CINRG Duchenne natural history study (2015-2022): 2022 interim analysis. J Neurol. 2023;270:4583. https:\/\/doi.org\/10.1007\/s00415-023-11864-2.","journal-title":"J Neurol"},{"key":"1593_CR8","doi-asserted-by":"publisher","first-page":"e126","DOI":"10.1016\/S1470-2045(23)00592-2","volume":"25","author":"SN Koole","year":"2024","unstructured":"Koole SN, Huisman AH, Timmers L, Westgeest HM, van Breugel E, Sonke GS, et al. Lessons learned from postmarketing withdrawals of expedited approvals for oncology drug indications. Lancet Oncol. 2024;25:e126\u201335. https:\/\/doi.org\/10.1016\/S1470-2045(23)00592-2.","journal-title":"Lancet Oncol"},{"key":"1593_CR9","doi-asserted-by":"publisher","first-page":"100660","DOI":"10.1016\/j.jcpo.2025.100660","volume":"47","author":"A Cramer","year":"2025","unstructured":"Cramer A, S\u00f8rup FKH, Christensen HR, Karstoft K, Petersen TS. Discrepancies in the therapeutic indications granted by the European Medicines Agency and the US Food and Drug Administration for new cancer drugs: an analysis of potential explanations. J Cancer Policy. 2025;47:100660. https:\/\/doi.org\/10.1016\/j.jcpo.2025.100660.","journal-title":"J Cancer Policy"},{"key":"1593_CR10","volume-title":"Pharmacopolitics: drug regulation in the United States and Germany","author":"AA Daemmrich","year":"2004","unstructured":"Daemmrich AA. Pharmacopolitics: drug regulation in the United States and Germany. University of North Carolina Press; 2004."},{"issue":"8","key":"1593_CR11","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.7326\/ANNALS-24-03242","volume":"178","author":"KN Vokinger","year":"2012","unstructured":"Vokinger KN, Serra-Burriel M, Glaus CEG, Welti L, Ross JS, Kesselheim AS. Differences between trial populations and approved label populations of new drugs in the United States and Europe (2012 to 2023): a cross-sectional study. Ann Intern Med. 2012;178(8):1127\u201337.","journal-title":"Ann Intern Med"},{"issue":"8","key":"1593_CR12","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1056\/NEJMsb2517623","volume":"394","author":"V Prasad","year":"2026","unstructured":"Prasad V, Makary MA. One pivotal trial, the new default option for FDA approval\u2014ending the two-trial dogma. N Engl J Med. 2026;394(8):815\u20137. https:\/\/doi.org\/10.1056\/NEJMsb2517623.","journal-title":"N Engl J Med"},{"key":"1593_CR13","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1586\/erp.11.12","volume":"11","author":"LD McLeod","year":"2011","unstructured":"McLeod LD, Coon CD, Martin SA, Fehnel SE, Hays RD. Interpreting patient-reported outcome results: US FDA guidance and emerging methods. Expert Rev Pharmacoecon Outcomes Res. 2011;11:163\u20139.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"1593_CR14","unstructured":"https:\/\/www.ema.europa.eu\/en\/partners-networks\/international-activities\/bilateral-interactions-non-eu-regulators\/united-states. Accessed 30 Sept 2024."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01593-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-026-01593-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01593-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T15:39:49Z","timestamp":1793461189000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-026-01593-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":14,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1593"],"URL":"https:\/\/doi.org\/10.1007\/s40261-026-01593-5","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"assertion":[{"value":"22 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author is a Scientific Advisory Group (SAG) neurology (consulting body for the EMA CHMP) core member. Otherwise, he has no competing interests to declare that are relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable (this is an opinion paper without original data).","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No datasets were generated or analyzed during the current study.","order":6,"name":"Ethics","label":"Availability of data and material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"C.C. is the sole author of this article, and as such takes full responsibility for its integrity.\u00a0The author would like to recognize\u00a0C.G. Goetz, G.T. Stebbins and C.Sampaio for their help in exloring these complex topics.","order":7,"name":"Ethics","label":"Authors contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}